PMID- 24595568
OWN - NLM
STAT- MEDLINE
DCOM- 20141124
LR  - 20140305
IS  - 1545-9616 (Print)
IS  - 1545-9616 (Linking)
VI  - 13
IP  - 3
DP  - 2014 Mar
TI  - Topical clofibrate improves symptoms in patients with atopic dermatitis and 
      reduces serum TARC levels: a randomized, double-blind, placebo-controlled pilot 
      study.
PG  - 259-63
AB  - BACKGROUND: Though topical corticosteroids (TC) are used for treating atopic 
      dermatitis (AD) as a standard, there exist several problems including topical 
      steroid addiction (TSA) or Red skin syndrome. Moreover, the number of patients, 
      who refrain from using TC because of steroid-phobia, is increasing. Recently, 
      topical PPAR alpha ligand application has been reported to improve experimental 
      allergic dermatitis. The purpose of this study was to investigate the short-term 
      efficacy and safety of topical clofibrate, one of PPAR alpha ligand, in such 
      steroid-phobic patients with AD. METHODS: This study was conducted as a 
      double-blind design to investigate the effects of random administration of 
      topical clofibrate and base (placebo) on skin manifestation and blood parameters 
      of patients for 2 weeks. Severity was digitized using severity scoring systems 
      for atopic dermatitis by the Japanese Dermatological Association (SSS-JDA) before 
      and after two weeks. Subjective severity of patients was evaluated using visual 
      analog scale (Pt-VAS). Serum thymus and activation-regulated chemokine (TARC) and 
      immunoglobulin E (IgE) were also investigated. RESULTS: Twenty patients were 
      enrolled, and 19 of 20 patients completed the study. In 19 patients, the value of 
      severity score using SSS-JDA was decreased significantly after administration of 
      topical clofibrate (P=0.001). Subjective evaluation using Pt-VAS (P=0.008) and 
      serum TARC levels (P=0.03) were also significantly decreased after two weeks of 
      topical clofibrate. There was not a significant difference in serum IgE levels. 
      No adverse effect was observed. CONCLUSIONS: Topical clofibrate is useful for 
      patients with AD especially who are reluctant to use topical steroids.
FAU - Fukaya, Mototsugu
AU  - Fukaya M
FAU - Kimata, Hajime
AU  - Kimata H
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Drugs Dermatol
JT  - Journal of drugs in dermatology : JDD
JID - 101160020
RN  - 0 (Chemokine CCL17)
RN  - 0 (Dermatologic Agents)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - HPN91K7FU3 (Clofibrate)
SB  - IM
MH  - Administration, Cutaneous
MH  - Adult
MH  - Chemokine CCL17/*blood
MH  - Clofibrate/administration & dosage/adverse effects/*therapeutic use
MH  - Dermatitis, Atopic/*drug therapy/pathology
MH  - Dermatologic Agents/administration & dosage/adverse effects/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/*blood
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2014/03/07 06:00
MHDA- 2014/12/15 06:00
CRDT- 2014/03/06 06:00
PHST- 2014/03/06 06:00 [entrez]
PHST- 2014/03/07 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - S1545961614P0259X [pii]
PST - ppublish
SO  - J Drugs Dermatol. 2014 Mar;13(3):259-63.